All In Biotech

Drug Trial Radar · NCT02612662

A Study to Assess the Safety and Tolerability of Single Doses of AZD4076 in Healthy Male Subjects

A Randomized, Single-blind, Placebo-controlled Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD4076 Tetracosasodium Following Single-ascending Dose Administration to Healthy Male Subjects

Last checked: Nov 20, 2026Latest source record: Oct 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

40

Actual

Start

Nov 24, 2015

Primary completion

Nov 4, 2017

Study completion Oct 27, 2025

Sponsor

Lead sponsor
AstraZenecaAstraZeneca (AZN)
Sponsor type
Industry
First posted
Nov 24, 2015

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Single (participant)
Primary purpose
Basic science
Who can join
Male only, from 18 years, up to 50 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This is a first-in-human (FIH) study designed to evaluate the safety, tolerability, and pharmacokinetics (PK) of AZD4076 tetracosasodium in healthy male subjects at increasing single doses

Conditions

  • Non-alcoholic Steatohepatitis (NASH)

Interventions

  • AZD4076Drug

    Subcutaneous (SC) administration of single ascending doses; there will be no more than 2 mL per syringe/injection

  • PlaceboDrug

    Subcutaneous (SC) administration of single ascending doses; there will be no more than 2 mL per syringe/injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The safety and tolerability of AZD4076 by assessment of blood pressureTime frame: From screening until 16 weeks postdose, up to 5 months
  2. The safety and tolerability of AZD4076 by assessment of pulseTime frame: From screening until 16 weeks postdose, up to 5 months
  3. The safety and tolerability of AZD4076 by assessment of oral temperatureTime frame: From screening until 72 hours postdose
  4. The safety and tolerability of AZD4076 by assessment of electrocardiogram readingsTime frame: From screening until 16 weeks postdose, up to 5 months
  5. The safety and tolerability of AZD4076 by assessment of digital electrocardiogram readingsTime frame: From predose until 72 hours postdose
  6. The safety and tolerability of AZD4076 by assessment of cardiac telemetryTime frame: On Day -1 and predose until 72 hours postdose
  7. The safety and tolerability of AZD4076 by assessment of physical examinationTime frame: From screening until 16 weeks postdose, up to 5 months
  8. The safety and tolerability of AZD4076 by assessing hematologyTime frame: From screening until 16 weeks postdose, up to 5 months
  9. The safety and tolerability of AZD4076 by assessing the injection siteTime frame: Postdose until 72 hours
  10. The safety and tolerability of AZD4076 by assessming the number of adverse eventsTime frame: From screening until 16 weeks postdose, up to 5 months
  11. The safety and tolerability of AZD4076 by assessing clinical chemistryTime frame: From screening until 16 weeks postdose, up to 5 months
  12. The safety and tolerability of AZD4076 by assessing urinalysisTime frame: From screening until 16 weeks postdose, up to 5 months
  13. The safety and tolerability of AZD4076 by assessing the number of participants with adverse eventsTime frame: From screening until 16 weeks postdose, up to 5 months

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Research Site

    Brooklyn, Maryland

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.